The European Commission and Moderna have reached an agreement to better address Member States’ needs for COVID-19 vaccines for the late summer and winter period. This will ensure national authorities have access to the vaccines, including variant-adapted vaccines if authorized, at the time they need them for their own vaccination campaigns and to support their global partners.
This agreement will adapt the originally agreed contractual delivery schedules. Doses originally scheduled for delivery in the summer will be delivered in September and during the autumn and winter period of 2022, when the Member States will more likely need additional stocks of vaccines for national campaigns and meeting their international solidarity commitments.
The agreement also ensures that, if one or more adapted vaccines receive marketing authorization, Member States may choose to receive those adapted vaccines under the current contract.
In this context, at the request of some Member States, the agreement also secures additional 15 million doses of Omicron-containing vaccine booster candidates from Moderna, subject to marketing authorization within timelines that would allow the use of these doses for their vaccination campaigns.
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Increasing COVID-19 vaccination and booster rates will be crucial as we plan ahead for the autumn and winter months. To best ensure our common preparedness, Member States must have the necessary tools. This includes vaccines adapted to variants, as and when they are authorized by the European Medicines Agency. This agreement will ensure that the Member States will have access to the vaccine doses they need at the right time to protect our citizens”.